scholarly journals Omega-3 Fatty Acids and Depression: Scientific Evidence and Biological Mechanisms

2014 ◽  
Vol 2014 ◽  
pp. 1-16 ◽  
Author(s):  
Giuseppe Grosso ◽  
Fabio Galvano ◽  
Stefano Marventano ◽  
Michele Malaguarnera ◽  
Claudio Bucolo ◽  
...  
Keyword(s):  
Fatty Acids ◽  
Depressive Disorders ◽  
Scientific Evidence ◽  
Bipolar Disorders ◽  
Inverse Correlation ◽  
Epidemiological Studies ◽  
Biological Properties ◽  
Omega 3 ◽  
Dietary Recommendations ◽  
Pufa Supplement

The changing of omega-6/omega-3 polyunsaturated fatty acids (PUFA) in the food supply of Western societies occurred over the last 150 years is thought to promote the pathogenesis of many inflammatory-related diseases, including depressive disorders. Several epidemiological studies reported a significant inverse correlation between intake of oily fish and depression or bipolar disorders. Studies conducted specifically on the association between omega-3 intake and depression reported contrasting results, suggesting that the preventive role of omega-3 PUFA may depend also on other factors, such as overall diet quality and the social environment. Accordingly, tertiary prevention with omega-3 PUFA supplement in depressed patients has reached greater effectiveness during the last recent years, although definitive statements on their use in depression therapy cannot be yet freely asserted. Among the biological properties of omega-3 PUFA, their anti-inflammatory effects and their important role on the structural changing of the brain should be taken into account to better understand the possible pathway through which they can be effective both in preventing or treating depression. However, the problem of how to correct the inadequate supply of omega-3 PUFA in the Westernized countries’ diet is a priority in order to set food and health policies and also dietary recommendations for individuals and population groups.

The Molecular Characterization and Biological Assessment of the Leaves Extracts of Loofah Reveal their Nutraceutical Potential

2020 ◽  
Vol 11 ◽  
Author(s):  
Takoua Ben Hlel ◽  
Feten Belhadj ◽  
Fatih Gül ◽  
Muhammed Altun ◽  
Ayşe Şahin Yağlıoğlu ◽  
...  
Keyword(s):  
Fatty Acids ◽  
Phenolic Compounds ◽  
Hela Cell ◽  
Arid Region ◽  
Biological Properties ◽  
Biological Assessment ◽  
Omega 3 ◽  
Hela Cell Lines ◽  
Semi Arid Region ◽  
Semi Arid

Background:: Luffa cylindrica is a plant that is widely distributed in Africa and Asia and it can be grown in regions with tropical or subtropical climates. Few patents dealt with Loofah biological properties, including some functional foods formulated from its leaves. Objective:: This study aimed to structurally and functionally characterize the bioactive compounds of L. cylindrica leaves grown in two different environments. Methods:: The extracts of L. cylindrica leaves collected from two Tunisian locations: Essouasi (LE), a semi-arid region and Medenine (LM) an arid region, were investigated for their phenolic compounds and fatty acids using HPLC/TOF-MS and GCMS techniques respectively. Furthermore, the antioxidant capacity was evaluated with DPPH, Chelating effect, Hydroxyl radical and Superoxide anion scavenging activities while the anticancer activity against HeLa cell lines was assessed using xCELLigence real time cell analyzer and lactate dehydrogenase cytotoxicity assay. Results:: The antiproliferative capacity of both extracts was time and dose-dependent with LE presenting the lowest HeLa cell index (CI = 0.035 ± 0.018, 250 μg/ml). LE also showed the best cytotoxic capacity (56.49 ± 0.8%) and antioxidant potential (IC50 = 54.41 ± 1.12 μg/ml for DPPH and 12.12 ± 0.07 μg/ml for chelating effet). 14 phenolic compounds were detected in LE with ferulic acid being the major compound (5128.5 ± 4.09 μg Phenols/g) while LM had only 6 phenolics. GCMS analysis showed the presence of omega-3 fatty acids in LE. Conclusions:: Our findings suggest that L. cylindrica leaves, especially when collected from semi-arid regions, are promising for formulating nutraceuticals of interest.

scholarly journals Polyunsaturated Fatty Acids: Impact on Health and Disease Status

2021 ◽  
Vol 2 (2) ◽  
pp. 12
Author(s):  
Samina Akbar ◽  
Muhammad Zeeshan Bhatti ◽  
Rida Fatima Saeed ◽  
Asma Saleem Qazi
Keyword(s):  
Fatty Acids ◽  
Polyunsaturated Fatty Acids ◽  
Disease Status ◽  
Epidemiological Studies ◽  
Lipid Lowering ◽  
Therapeutic Effects ◽  
Omega 3 ◽  
Beneficial Effects ◽  
Omega 6 ◽  
Health And Disease

Over the last decades, the polyunsaturated fatty acids (PUFAs) have been largely explored not only for their nutritional value but also for the numerous biological functions and therapeutic effects. The serum and erythrocyte levels of PUFAs depend on the genetic control of metabolism as well as the dietary intake and are considered to reflect the health and disease status of an individual. Two families of PUFAs, omega-3 (n-3) and omega-6 (n-6), have gained much attention because of their involvement in the production of bioactive lipid mediators and therefore, a balanced omega-6/omega-3 ratio is crucial in maintaining the overall health of an individual. Omega-3 PUFAs, notably eicosapentaenoic acid (EPA, 20:5n-3) and docosahexaenoic acid (DHA, 22:6n-3) have been shown to exert beneficial effects, possibly due to their lipid-lowering, anti-inflammatory, anti-hypertensive and cardioprotective effects, whereas omega-6 fatty acids such as arachidonic acid (ARA, 20:4n-6) exhibit the opposite properties. Even though, numerous epidemiological studies and clinical interventions have clearly established the effectiveness of omega-3 PUFAs in various pathological conditions including dyslipidemia, obesity, diabetes, cancer, cardiovascular and neurodegenerative diseases, some controversies do exist about the beneficial effects of omega-3 PUFAs and need to be clarified. Larger clinical trials with extended follow-up periods are required along with a careful dose selection, in order to confirm the clinical significance and efficacy of omega-3 PUFAs as therapeutic agents.

scholarly journals Omega-3 fatty acids and cardiovascular disease: epidemiology and effects on cardiometabolic risk factors

2014 ◽  
Vol 5 (9) ◽  
pp. 2004-2019 ◽  
Author(s):  
Trevor A. Mori
Keyword(s):  
Risk Factors ◽  
Cardiovascular Disease ◽  
Fatty Acids ◽  
Docosahexaenoic Acid ◽  
Cardiometabolic Risk ◽  
Epidemiological Studies ◽  
Fish Oils ◽  
Omega 3 Fatty Acids ◽  
Omega 3 ◽  
Disease Epidemiology

Clinical and epidemiological studies provide support that the polyunsaturated omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid from fish and fish oils are cardioprotective, particularly in the setting of secondary prevention.

scholarly journals Dietary sources of omega 3 fatty acids: public health risks and benefits

2012 ◽  
Vol 107 (S2) ◽  
pp. S23-S52 ◽  
Author(s):  
J. A. Tur ◽  
M. M. Bibiloni ◽  
A. Sureda ◽  
A. Pons
Keyword(s):  
Public Health ◽  
Fatty Acids ◽  
Health Risks ◽  
Scientific Evidence ◽  
Good Health ◽  
Omega 3 Fatty Acids ◽  
Omega 3 ◽  
Public Health Risks ◽  
Risks And Benefits ◽  
Health Risks And Benefits

Omega 3 fatty acids can be obtained from several sources, and should be added to the daily diet to enjoy a good health and to prevent many diseases. Worldwide, general population use omega-3 fatty acid supplements and enriched foods to get and maintain adequate amounts of these fatty acids. The aim of this paper was to review main scientific evidence regarding the public health risks and benefits of the dietary sources of omega-3 fatty acids. A systematic literature search was performed, and one hundred and forty-five articles were included in the results for their methodological quality. The literature described benefits and risks of algal, fish oil, plant, enriched dairy products, animal-derived food, krill oil, and seal oil omega-3 fatty acids.

scholarly journals Omega-3 fatty acids for the treatment of depressive disorders in children and adolescents: a meta-analysis of randomized placebo-controlled trials

2019 ◽  
Vol 13 (1) ◽  
Author(s):  
Li Zhang ◽  
Huan Liu ◽  
Li Kuang ◽  
Huaqing Meng ◽  
Xinyu Zhou
Keyword(s):  
Fatty Acids ◽  
Depressive Symptoms ◽  
Children And Adolescents ◽  
Depressive Disorders ◽  
Response Rate ◽  
Risk Of Bias ◽  
Controlled Trials ◽  
Omega 3 Fatty Acids ◽  
Omega 3 ◽  
Subgroup Analyses

Abstract Background To investigate the efficacy and safety of omega-3 fatty acids (O3FA) in treating depressive disorders in children and adolescents. Method We conducted a comprehensive search in electronic databases and hand-searched articles included for relevant studies. We included randomized controlled trials which studied on O3FA for treatment of children and adolescents with depression. The standard mean differences (SMDs) and the odds ratios (ORs) with 95% confidence intervals (CIs) were estimated by a random-effects model. The primary outcomes were end-point depressive symptoms scores (efficacy) and all-cause discontinuation (safety). The secondary outcome of response rate was also assessed. Subgroup analyses were performed by age, severity of depression and dosage. Risk of bias assessment was performed based on the Jadad score and the Cochrane Collaboration’s risk-of-bias method. Results A total of four studies with 153 participants were included. In terms of efficacy, there was no significant difference of end-point depressive symptoms scores between O3FA and placebo (SMD = − 0.12, 95% CI − 0.53 to 0.30, P = 0.58; I2= 30%). In terms of safety, the all-cause discontinuation showed no statistical significance between O3FA and placebo (OR = 1.3, 95% CI 0.58 to 2.93, P = 0.53; I2= 0%). The response rate of O3FA was also not significant better than that of placebo (OR = 1.57, 95% CI 0.26 to 9.39, P = 0.62; I2= 71%). Besides, there were also no significant differences in those subgroup analyses outcomes. The risk of bias of included trials were not high. Conclusions Only considering the limited evidence of O3FA in the acute treatment of major depressive disorder, it did not seem to offer a clear advantage for children and adolescents.

scholarly journals Role of Omega-3 Fatty Acids in the Treatment of Depressive Disorders: A Comprehensive Meta-Analysis of Randomized Clinical Trials

PLoS ONE ◽  
2014 ◽  
Vol 9 (5) ◽  
pp. e96905 ◽  
Author(s):  
Giuseppe Grosso ◽  
Andrzej Pajak ◽  
Stefano Marventano ◽  
Sabrina Castellano ◽  
Fabio Galvano ◽  
...  
Keyword(s):  
Fatty Acids ◽  
Clinical Trials ◽  
Depressive Disorders ◽  
Randomized Clinical Trials ◽  
Meta Analysis ◽  
Omega 3 Fatty Acids ◽  
Omega 3

Omega 3 and Depression - State of Art

2009 ◽  
Vol 24 (S1) ◽  
pp. 1-1
Author(s):  
J. Pereira ◽  
A. Abreu ◽  
D. Fonte ◽  
S. Carvalho
Keyword(s):  
Fatty Acids ◽  
Major Depression ◽  
Blood Cells ◽  
Plasma Concentrations ◽  
Epidemiological Studies ◽  
Omega 3 ◽  
Response Curves ◽  
Coronary Syndrome ◽  
Relevant Dose ◽  
Depression Disorder

Aims:Docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA) are omega-3 polyunsaturated fatty acids (ω-3 PUFAs) involved in the structure and function of cell membranes in the brain. Because both compounds must be obtained from diet, by eating oily fish or fish oil, the consumption of fish or supplements of omega-3 could be correlated with neuropsychiatric disorders, as depression disorder.Methods:Search of relevant studies in Scirus database.Results:Epidemiological studies suggest that populations with high consumption of fish have low annual prevalence of major depression. Laboratorial research verified that major depression in acute coronary syndrome patients is associated with significantly lower plasma levels of ω-3 PUFAs, in particular of DHA; red blood cells membrane levels of total ω-3 PUFAs and of DHA are significantly lower in depressive patients; low plasma concentrations of DHA predict low concentrations of 5-hydroxyindolacetic acid, a marker of brain serotonin turnover, which, in turn, is strongly associated with depression and suicide. Clinical trials demonstrated the efficiency of EPA in the alleviating the symptoms of major depression in adults, childhood depression and postpartum depression.Conclusions:Although the depression appears to be related with low levels of DHA in plasma and blood cells, controlled trials have found no effect of DHA supplementation in depression. On the contrry, EPA might have an adjunctive therapeutic value in the treatment of depression disorder. Much research is required to compare the effectiveness of the different fatty acids in the treatment of depressive disorder, as well as the relevant dose-response curves.

Sign in / Sign up

Export Citation Format

Share Document